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Background-—Relatively little is known about the quality of care and outcomes for hospitalized ischemic stroke patients with
chronic kidney disease (CKD). We examined quality of care and in-hospital prognoses among patients with CKD in the Get With The
Guidelines–Stroke (GWTG-Stroke) program
Methods and Results-—We analyzed 679 827 patients hospitalized with ischemic stroke from 1564 US centers participating in the
GWTG-Stroke program between January 2009 and December 2012. Use of 7 predeﬁned ischemic stroke performance measures,
composite “defect-free” care compliance, and in-hospital mortality were examined based on glomerular ﬁltration rate (GFR)
categorized as a dichotomous (+CKD as <60) or rank-ordered variable: normal (≥90), mild (≥60 to <90), moderate (≥30 to <60),
severe (≥15 to <30), and kidney failure (<15 or dialysis). There were 236 662 (35%) ischemic stroke patients with CKD. Patients
with severe renal dysfunction or failure were signiﬁcantly less likely to receive guideline-based therapies. Compared with patients
with normal kidney function (≥90), those with CKD (adjusted OR 0.91 [95% CI: 0.89 to 0.92]), moderate dysfunction (adjusted OR
0.94 [95% CI: 0.92 to 0.97]), severe dysfunction (adjusted OR 0.80 [95% CI: 0.77 to 0.84]), or failure (adjusted OR 0.72 [95% CI:
0.68 to 0.0.76]), were less likely to receive 100% defect-free care measure compliance. Inpatient mortality was higher for patients
with CKD (adjusted odds ratio 1.44 [95% CI: 1.40 to 1.47]), and progressively rose with more severe renal dysfunction.
Conclusions-—Despite higher in-hospital mortality rates, ischemic stroke patients with CKD, especially those with greater severity
of renal dysfunction, were less likely to receive important guideline-recommended therapies. (J Am Heart Assoc. 2014;3:
e000905 doi: 10.1161/JAHA.114.000905)
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C
hronic kidney disease (CKD) is a frequent comorbidity
among patients with symptomatic cerebrovascular dis-
ease,
1 which has been independently linked with poorer
prognoses among stroke patients including greater short- and
long-term risk of death.
2–6 Because most patients with CKD
die of vascular causes, not progression to end-stage renal
disease, more precise quantiﬁcation of the co-morbid pres-
ence and effects of CKD among patients hospitalized with
acute vascular events may be insightful.
1 Moreover, it is
conceivable that optimal evidence-based treatment of hospi-
talized patients with both symptomatic vascular disease and
CKD may improve clinical outcomes.
1 Recognizing this, the
American Heart Association issued an expert advisory recom-
mending that healthcare providers aggressively manage their
vascular disease patients with CKD in order to sever potential
causal pathways between the kidney and the heart.
7 However,
little if anything is known about the quality of evidence-based
care provided to hospitalized stroke patients with CKD, and
whether such care may differ by level of kidney dysfunction.
The objective of this study was 3-fold: (1) properly quantify
the prevalence of CKD among hospitalized ischemic stroke
patients and its association with in-hospital outcomes; (2)
compare the quality of stroke-related care (ie, interventions
addressing the management of stroke) among ischemic stroke
patients with and without CKD; (3) assess whether care quality
and in-hospital outcomes vary among ischemic stroke patients
by CKD stage.
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Patient Population
We used data from the Get With The Guidelines-Stroke
(GWTG-Stroke) program database. Details of the design and
conduct of the program have been previously described.
8
Brieﬂy, the program is a voluntary, national, quality-improve-
ment initiative sponsored by the American Heart Association
and American Stroke Association, geared at fostering
improved adherence to guideline-based care in patients
hospitalized with stroke and TIA. Brieﬂy, participating hospi-
tals use an Internet-based Patient Management Tool (Out-
come Sciences Inc, a Quintiles Company) to enter data,
receive decision support, and obtain feedback through on-
demand reports of performance on quality measures. GWTG-
Stroke participating hospitals record data from consecutive
stroke and TIA hospital admissions. Case ascertainment is
done via clinical identiﬁcation during the hospital encounter,
retrospective surveillance of International Classiﬁcation of
Diseases, ninth Revision codes, or both. Trained hospital
personnel extract data on demographics, medical history,
neuroimaging, in-hospital treatment, and discharge charac-
teristics. While the GWTG-Stroke program is overrepresented
with larger academic teaching hospitals, the patient demo-
graphics and comorbidites are similar to those described in
other stroke registries and administrative databases.
8 Out-
come Sciences serves as the data collection and coordination
center for GWTG. The Duke Clinical Research Institute serves
as the data analysis center and has an agreement to analyze
the aggregate de-identiﬁed data for research purposes. Each
participating hospital received either human research
approval to enroll cases without individual patient consent
under the common rule or a waiver of authorization and
exemption from subsequent review by their Institutional
Review Board.
Performance Measures
Seven performance measures, pre-selected by the GWTG-
Stroke program as primary targets for stroke quality-improve-
ment efforts based on prevailing expert consensus treatment
guidelines,
9,10 were used to compare the quality of stroke-
related care between ischemic stroke admissions with and
without CKD. Acute ischemic stroke performance measures
were: (1) intravenous tissue plasminogen activator in patients
who arrive <2 hours after symptom onset and with no
contraindications to treatment; (2) antithrombotic medication
(includes any aspirin, aspirin/dipyridamole, ticlopidine, clop-
idogrel, unfractionated heparin, low-molecular-weight heparin,
and warfarin) administered within 48 hours of admission; and
(3) deep vein thrombosis prophylaxis (includes heparins,
heparinoids, other anticoagulants, or pneumatic compression
devices) within 48 hours of admission in non-ambulatory
patients. Discharge ischemic stroke performance measures
were: (1) antithrombotic (includes any aspirin, aspirin/dipy-
ridamole, ticlopidine, clopidogrel, unfractionated heparin, low-
molecular-weight heparin, and warfarin) medication; (2) anti-
coagulation (includes therapeutic doses of warfarin, hepari-
noid), or other anticoagulants such as direct thrombin
inhibitors) for patients with a diagnosis of atrial ﬁbrillation
or ﬂutter (paroxysmal, persistent, or permanent); (3) choles-
terol treatment (includes statins, ﬁbrates niacin, binding
resins, or selective cholesterol absorption inhibitors) if low-
density lipoprotein cholesterol (LDL-C) >100 mg/dL or if LDL-
C is not documented; and (4) counseling or medication for
smoking cessation for patients who are current smokers (any
cigarettes in past year; “smoking cessation”). The GTWG-
Stroke assessment tool allows clinicians to check a box
indicating a contraindication to a given performance measure
and in such cases, compliance with the performance measure
is seen as being met. To summarize the overall quality of
stroke-related care, we calculated a defect-free measure of
care, which is a binary variable calculated as the proportion of
patients who received all of the interventions for which they
were eligible.
CKD Deﬁnitions
The serum creatinine level obtained at the time of hospital
admission was used to determine the estimated glomerular
ﬁltration rate. Estimated glomerular ﬁltration rate per the
Modiﬁcation of Diet in Renal Disease Study Group equation
was calculated for each patient using the abbreviated
Modiﬁcation of Diet in Renal Disease formula: estimated
GFR (mL/min per 1.73 m
2)=1869[serum creatinine]
1.159age0.2039[0.742 if female]9[1.21 if black].
11 CKD
was deﬁned as eGFR<60 mL/min per 1.73 m
2. GWTG-Stroke
patients without CKD (controls) were the referent group for
purposes of comparison. We then categorized patients by
kidney function (GFR in mL/min per 1.73 m
2) using modiﬁed
deﬁnitions from the National Kidney Foundation—Kidney
Disease Outcomes Quality Initiative clinical practice
guidelines: normal (GFR≥90), mild (60≤GFR<90), moderate
(30≤GFR<60), severe (15≤GFR<30), and kidney failure
(GFR<15).
Statistical Analysis
Patient demographic and clinical variables, hospital-level
characteristics, and compliance with the individual and
summary quality-of-care measures were compared between
patients with and without CKD. Percentages and meansSD
were reported for categorical and continuous variables,
respectively. Pearson v
2 test and Wilcoxon rank-sum tests
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variables, respectively, between patients with and without
CKD. To compare variables among CKD stages we used
Pearson v
2 test and Kruskal Wallis tests, respectively. The
relationship between CKD status (yes versus no) and different
levels of renal function versus compliance with individual
performance measures, as well as the defect-free summary
measure of care were further examined using multivariable
logistic regression models. To account for within-hospital
clustering, generalized estimating equations were used to
generate unadjusted and adjusted models.
12 Conﬁdence
intervals and P values were computed using Wald tests. The
adjusted models included the following pre-speciﬁed potential
confounders: age, sex, race, medical history (including atrial
ﬁbrillation, prosthetic heart valve, previous stroke/TIA, coro-
nary heart disease, or previous myocardial infarction [coro-
nary artery disease/previous MI], carotid stenosis, peripheral
vascular disease, hypertension, diabetes, dyslipidemia, heart
failure, and current smoking), systolic blood pressure (SBP) at
admission, hospital size, region, teaching status, primary
stroke center status and the number of annual stroke
discharges from each hospital. Missing values for medical
history (0.22%) were imputed to no history and for SBP
(2.62%) to the median value. Patients with missing informa-
tion in 1 or more hospitals characteristics were excluded from
the models (less than 0.25%).
Similar multivariable logistic regression analyses were
performed to explore the relationship between CKD status
and 2 other binary outcome measures (ie, in-hospital mortality
and discharge status [home versus other]). We included the
same set of pre-speciﬁed potential confounders in all 3 of
these outcomes-based models, and we chose not to adjust for
differences in performance measures because of the inherent
problem of confounding by indication (ie, the tendency for
patients with inherently poorer prognosis to receive less care).
Only eligible patients for each outcome with complete data are
included ineach model.Wealsoconductedsensitivityanalyses
by generating models that included all of the aforementioned
variables and the measure of stroke severity (NIH Stroke Scale
Score) in the subgroup of patients in which this measure of
stroke severity was documented (NIHSS missing in 36.1% of
study population). NIHSS was analyzed as a continuous
variable. All tests are 2-tailed with P<0.05 considered as the
level of statistical signiﬁcance. All statistical analyses were
performed using SAS software (version X SAS Institute Inc).
Results
Of 858 124 ischemic stroke admissions at 1624 hospitals
during the study period, after excluding patients with serum
creatinine values missing (n=151 634), reported serum
creatinine value out of range (ie, 0 or >20 mg/dL, n=2195),
sex or race variable missing (n=979), and patient transferred
out/left against medical advice/discharge status missing/
(n=23 489), there were 679 827 ischemic stroke admissions.
An analysis of just those patients with serum creatinine values
available versus missing revealed generally similar demo-
graphic and clinical characteristics, and where differences
existed they were small and unlikely to be of major relevance
(Table 1).
Among these ischemic stroke admissions (n=679 827),
over one-third (34.8%; n=236 662) met the deﬁnition of CKD.
Patients with CKD were older (mean, 76.2 versus 68 years),
more likely to be female or white, and more likely to have a
medical history of stroke/TIA, carotid stenosis, coronary
artery disease/previous MI, hypertension, dyslipidemia, dia-
betes, atrial ﬁbrillation/ﬂutter, peripheral arterial disease, and
heart failure, but they were less likely to be current smokers.
Patients with CKD had more severe strokes (mean NIH stroke
scale score 8.0 versus 6.7). Table 2 compares the demo-
graphic and clinical characteristics of ischemic stroke
patients by presence of CKD and stage of kidney dysfunction.
Compared with patients with earlier stages of kidney
dysfunction (mild or moderate), those with more advanced
stages of dysfunction (severe or failure) were older, more
likely to be of black race, and much more likely to have a
medical history of diabetes, peripheral arterial disease, and
heart failure, but less likely to be of independent ambulatory
status prior to admission. Patients with more advanced stages
of kidney dysfunction (versus earlier stages) were more likely
to present with altered level of consciousness or lower
admission systolic blood pressure levels, but less likely to
have strokes of mild severity.
There were signiﬁcantly higher rates of compliance with all
7 performance measures and defect-free care among those
without CKD compared with those with CKD. However, for
some of the measures these differences were numerically
rather modest. In-hospital outcomes were much worse for
those with CKD versus without CKD across all 3 endpoints
studied including in-hospital case fatality (Table 3). Table 4
shows a comparison of frequencies among ischemic stroke
patients with various stages of kidney dysfunction. Signiﬁ-
cantly lower rates of compliance were observed with all 7
performance measures and defect-free care among those
patients with more advanced stages of kidney dysfunction
(versus earlier stages), but these differences were numerically
very modest with the exception of patients presenting within
2 hours of ictus receiving IV tPA, for which there was a lower
compliance rate ranging from 4 to 10 percentage points in
those in advanced versus earlier stages of dysfunction
(Table 4). In-hospital outcomes were much worse for
advanced versus earlier stages of renal dysfunction including
in-hospital case fatality (Table 4).
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comparing ischemic stroke patients with various stages of
kidney disease to those with normal renal function for the pre-
speciﬁed stroke hospitalization performance measures and
the summary defect-free care measure. Compared with
patients with normal kidney function, those with CKD were
signiﬁcantly less likely to receive smoking cessation counsel-
ing at discharge (adjusted OR 0.86, 95% CI: 0.80 to 0.93),
antithrombotic prescribed within 48 hours of admission
(adjusted OR 0.82, 95% CI: 0.79 to 0.85), antithrombotic at
discharge (adjusted OR 0.87, 95% CI: 0.83 to 0.91), antico-
agulation at discharge if there was a diagnosis of atrial
ﬁbrillation or atrial ﬂutter (adjusted OR 0.90, 95% CI: 0.85 to
0.95), lipid modiﬁer at discharge (adjusted OR 0.96, 95% CI:
0.93 to 0.99), and defect-free care (adjusted OR 0.91, 95% CI:
0.89 to 0.92).
Analysis by stage of kidney dysfunction (Table 5), shows
that compared with patients with normal kidney function, for
patients presenting within 2 hours of stroke onset who
received IV tPA or for lipid modiﬁer medication prescribed at
discharge, those with severe dysfunction or renal failure
versus normal kidney function were less likely to be in
Table 1. Baseline Demographic and Clinical Characteristics by Missing Serum Creatinine Variable Status
Variable Description Overall (N=826 828)
Serum Creatinine Not
Missing (N=679 827)
Serum Creatinine
Missing (N=147 001) P Value
Demographics
Age (18 to 110), y Mean 70.85 70.83 70.91 0.1069
Standard deviation 14.62 14.63 14.61
Minimum 18.00 18.00 18.00
Maximum 110.00 110.00 110.00
Sex Female 42 8519 51.83 352 967 51.92 75 552 51.40 0.0003
Race/ethnicity White (n, %) 584 486 70.69 480 323 70.65 104 163 70.86 <0.0001
Black (n, %) 134 936 16.32 114 281 16.81 20 655 14.05
Hispanic (n, %) 53 998 6.53 44 306 6.52 9692 6.59
Medical history
Atrial fibrillation/flutter Yes (n, %) 148 626 18.10 121 918 17.97 26 708 18.71 <0.0001
Coronary artery disease Yes (n, %) 211 217 25.73 175 430 25.86 35 787 25.07 <0.0001
Carotid stenosis Yes (n, %) 32 417 3.95 26 454 3.90 5963 4.18 <0.0001
Diabetes mellitus Yes (n, %) 266 500 32.46 221 128 32.60 45 372 31.79 <0.0001
Dyslipidemia Yes (n, %) 351 473 42.81 289 409 42.67 62 064 43.48 <0.0001
Hypertension Yes (n, %) 624 904 76.11 518 145 76.39 106 759 74.80 <0.0001
Prosthetic heart valve Yes (n, %) 10 893 1.33 8994 1.33 1899 1.33 0.8920
Peripheral vascular disease Yes (n, %) 38 970 4.75 32 013 4.72 6957 4.87 0.0125
Heart failure Yes (n, %) 71 959 8.76 59 341 8.75 12 618 8.84 0.2639
Smoker Yes (n, %) 150 389 18.32 124 675 18.38 25 714 18.02 0.0012
Previous stroke/transient ischemic attack Yes (n, %) 254 577 31.01 211 268 31.15 43 309 30.34 <0.0001
Evaluation
National Institute of Health Stroke Scale score 0 to 9 (n, %) 385 778 46.66 316 733 46.59 69 045 46.97 <0.0001
Door to CT scan ≤25 minutes Yes (n, %) 154 917 18.74 128 019 18.83 26 898 18.30 0.0081
Pre-admission drugs
Anticoagulants Yes (n, %) 84 706 10.24 75 744 11.14 8962 6.10 0.7098
Antiplatelets Yes (n, %) 347 104 41.98 310 558 45.68 36 546 24.86 0.0216
Anti-hypertensives Yes (n, %) 525 329 63.54 477 350 70.22 47 979 32.64 <0.0001
Cholesterol reducers Yes (n, %) 346 488 41.91 284 590 41.86 61 898 42.11 <0.0001
Anti-diabetics Yes (n, %) 192 618 23.30 175 644 25.84 16 974 11.55 <0.0001
CT indicates computed tomography.
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HTable 3. Frequencies Comparing Ischemic Stroke Patients With Chronic Kidney Disease (CKD) to Those Without CKD for 7
Performance Measures, a Summary Defect-Free Care Measure, and In-Hospital Outcomes
Variable Overall (N=679 827)
No CKD (GFR≥60)
(N=443 165)
CKD (GFR<60)
(N=236 662) P Value
Performance measures n % n % n %
Patients presenting within 2 hours of ictus
receive IV tPA
35 330 78.03 23 039 78.55 12 291 77.08 0.0003
Antithrombotic prescribed within 48 hours of admission 414 672 96.85 263 202 97.12 151 470 96.39 <0.0001
Deep venous thrombosis prophylaxis 322 251 97.50 211 230 97.59 111 021 97.34 <0.0001
Antithrombotic prescribed at discharge 583 330 98.60 390 884 98.66 192 446 98.49 <0.0001
Anticoagulation prescribed at discharge for AF patients 86 199 94.61 51 070 95.05 35 129 93.98 <0.0001
Smoking cessation intervention provided at discharge 112 020 97.12 88 739 97.32 23 281 96.35 <0.0001
Lipid-lowering agent prescribed at discharge 315 999 94.40 209 787 94.60 106 212 94.02 <0.0001
Composite measure
Defect-free: compliance 100% 590 005 90.81 390 431 91.27 199 574 89.93 <0.0001
In-hospital outcomes
In-hospital case fatality 32 290 4.75 16 786 3.79 15 504 6.55 <0.0001
In-hospital case fatality or discharged to hospice 61 687 9.07 31 580 7.13 30 107 12.72 <0.0001
Discharge destination other than directly home 314 765 8.61 190 252 44.62 124 513 56.30 <0.0001
AF indicates atrial ﬁbrillation; GFR, glomerular ﬁltration rate.
Table 4. Frequencies Comparing Ischemic Stroke Patients With Various Categories of Chronic Kidney Disease (CKD) to Those
Without CKD for 7 Performance Measures, a Summary Defect-Free Care Measure, and In-Hospital Outcomes
Variable
No CKD (GFR≥90)
(N=163 772)
Mild CKD
(60≤GFR<90)
(N=279 393)
Moderate CKD
(30≤GFR<60)
(N=194 030)
Severe CKD
(15≤GFR<30)
(N=28 583)
Renal Failure
(GFR<15)
(N=14 049) P Value
Performance measures n % n % n % n % n %
Patients presenting within 2 hours of
ictus receive IV tPA
7480 78.21 15 559 78.72 10 678 77.98 1185 73.06 428 67.94 0.0002
Antithrombotic prescribed within
48 hours of admission
96 901 96.97 166 301 97.21 122 656 96.75 19 097 95.22 9717 94.21 <0.0001
Deep venous thrombosis prophylaxis 80 105 97.62 131 125 97.57 91 000 97.40 13 375 97.17 6646 96.82 <0.0001
Antithrombotic prescribed at discharge 146 502 98.55 244 382 98.73 159 897 98.62 21 645 97.92 10 904 97.78 0.0004
Anticoagulation prescribed at discharge
for AF patients
13 457 94.78 37 613 95.15 30 423 94.36 3432 91.74 1274 91.20 <0.0001
Smoking cessation intervention provided
at discharge
44 581 97.47 44 158 97.17 19 178 96.53 2629 95.81 1474 95.04 <0.0001
Lipid-lowering agent prescribed at
discharge
76 542 94.74 133 245 94.51 88 724 94.11 11 998 93.57 5490 93.51 <0.0001
Composite measure
Defect-free: compliance 100% 145 339 91.37 245 092 91.21 164 938 90.31 23 136 88.42 11 500 87.61 <0.0001
In-hospital outcomes
In-hospital case fatality 5551 3.39 11 235 4.02 11 451 5.90 2775 9.71 1278 9.10 <0.0001
In-hospital case fatality or discharged to
hospice
9842 6.01 21 738 7.78 23 035 11.87 4950 17.32 2122 15.10 <0.0001
Discharge destination other than directly
home
65 560 41.44 12 4692 46.50 101 764 55.74 15 811 61.26 6938 54.33 <0.0001
AF indicates atrial ﬁbrillation; GFR, glomerular ﬁltration rate.
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HTable 5. Unadjusted and Adjusted Odds Ratios Comparing Ischemic Stroke Patients With Various Stages of Kidney Dysfunction to
Those With Normal Kidney Function for 7 Performance Measures and a Summary Defect-Free Care Measure
Process Measures Category of CKD Unadjusted OR (95% CI)* P Value Adjusted OR (95% CI)* P Value
Patients presenting within 2 hours of
ictus receive IV tPA
CKD (GFR<60) 0.96 (0.93 to 0.99) 0.0158 0.96 (0.91 to 1.01) 0.0903
Patients presenting within 2 hours of
ictus receive IV tPA
Mild kidney dysfunction
(GFR ≥60 to <90)
1.04 (1.00 to 1.08) 0.0571 1.06 (1.00 to 1.12) 0.0585
Patients presenting within 2 hours of
ictus receive IV tPA
Moderate kidney dysfunction
(GFR ≥30 to <60)
1.02 (0.97 to 1.07) 0.4550 1.04 (0.97 to 1.11) 0.3105
Patients presenting within 2 hours of
ictus receive IV tPA
Severe kidney dysfunction
(GFR ≥15 to <30)
0.86 (0.79 to 0.93) 0.0004 0.85 (0.76 to 0.96) 0.0088
Patients presenting within 2 hours of
ictus receive IV tPA
Renal failure (GFR<15) 0.74 (0.65 to 0.84) <0.0001 0.72 (0.61 to 0.85) 0.0001
Deep venous thrombosis prophylaxis CKD (GFR<60) 0.93 (0.89 to 0.97) 0.0003 0.96 (0.91 to 1.00) 0.0619
Deep venous thrombosis prophylaxis Mild kidney dysfunction
(GFR ≥60 to <90)
1.00 (0.95 to 1.05) 0.9602 1.02 (0.96 to 1.07) 0.6040
Deep venous thrombosis prophylaxis Moderate kidney dysfunction
(GFR ≥30 to <60)
0.95 (0.90 to 1.00) 0.0480 0.98 (0.93 to 1.05) 0.6012
Deep venous thrombosis prophylaxis Severe kidney dysfunction
(GFR ≥15 to <30)
0.89 (0.80 to 0.98) 0.0146 0.94 (0.84 to 1.05) 0.2477
Deep venous thrombosis prophylaxis Renal failure (GFR<15) 0.79 (0.70 to 0.90) 0.0003 0.83 (0.72 to 0.95) 0.0068
Smoking cessation intervention
provided at discharge
CKD (GFR<60) 0.77 (0.73 to 0.82) <0.0001 0.86 (0.80 to 0.93) 0.0001
Smoking cessation intervention
provided at discharge
Mild kidney dysfunction
(GFR ≥60 to <90)
0.89 (0.85 to 0.94) <0.0001 0.95 (0.88 to 1.02) 0.1604
Smoking cessation intervention
provided at discharge
Moderate kidney dysfunction
(GFR ≥30 to <60)
0.76 (0.71 to 0.81) <0.0001 0.87 (0.80 to 0.96) 0.0034
Smoking cessation intervention
provided at discharge
Severe kidney dysfunction
(GFR ≥15 to <30)
0.66 (0.58 to 0.74) <0.0001 0.76 (0.65 to 0.89) 0.0009
Smoking cessation intervention
provided at discharge
Renal failure (GFR<15) 0.59 (0.48 to 0.71) <0.0001 0.62 (0.48 to 0.78) 0.0001
Antithrombotic prescribed within
48 hours of admission
CKD (GFR<60) 0.80 (0.78 to 0.83) <0.0001 0.82 (0.79 to 0.85) <0.0001
Antithrombotic prescribed within
48 hours of admission
Mild kidney dysfunction
(GFR ≥60 to <90)
1.05 (1.01 to 1.10) 0.0075 1.08 (1.03 to 1.13) 0.0011
Antithrombotic prescribed within
48 hours of admission
Moderate kidney dysfunction
(GFR ≥30 to <60)
0.91 (0.88 to 0.95) <0.0001 0.96 (0.91 to 1.01) 0.1164
Antithrombotic prescribed within
48 hours of admission
Severe kidney dysfunction
(GFR ≥15 to <30)
0.64 (0.60 to 0.69) <0.0001 0.67 (0.62 to 0.73) <0.0001
Antithrombotic prescribed within
48 hours of admission
Renal Failure (GFR<15) 0.54 (0.49 to 0.58) <0.0001 0.54 (0.49 to 0.59) <0.0001
Antithrombotic prescribed at discharge CKD (GFR<60) 0.92 (0.89 to 0.95) <0.0001 0.87 (0.83 to 0.91) <0.0001
Antithrombotic prescribed at discharge Mild kidney dysfunction
(GFR ≥60 to <90)
1.12 (1.07 to 1.17) <0.0001 1.08 (1.01 to 1.14) 0.0055
Antithrombotic prescribed at discharge Moderate kidney dysfunction
(GFR ≥30 to <60)
1.06 (1.01 to 1.11) 0.0122 0.98 (0.92 to 1.05) 0.5877
Antithrombotic prescribed at discharge Severe kidney dysfunction
(GFR ≥15 to <30)
0.76 (0.70 to 0.82) <0.0001 0.68 (0.61 to 0.76) <0.0001
Antithrombotic prescribed at discharge Renal Failure (GFR<15) 0.72 (0.65 to 0.81) <0.0001 0.68 (0.59 to 0.78) <0.0001
Anticoagulation prescribed at discharge
for AF patients
CKD (GFR<60) 0.85 (0.81 to 0.89) <0.0001 0.90 (0.85 to 0.95) 0.0001
Continued
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48 hours of admission or at discharge, as well as anticoag-
ulation prescribed at discharge in patients with atrial ﬁbrilla-
tion or atrial ﬂutter, those with severe dysfunction and renal
failure were less likely to be in compliance, but those with
mild dysfunction were more likely to be in compliance; and for
defect-free care, those with moderate dysfunction, severe
dysfunction, and renal failure were less likely to be in
compliance.
Table 6 shows unadjusted and adjusted odds ratios
comparing ischemic stroke patients with various stages of
kidney dysfunction to those with normal function for the 3
outcome measures. In-hospital case fatality was higher for
patients with CKD versus no CKD (adjusted OR 1.44, 95% CI:
1.40 to 1.47), and progressively rose with more severe renal
dysfunction to the extent that patients with renal failure had
well over twice the odds of dying in the hospital compared to
those without CKD (adjusted OR 2.39, 95% CI: 2.22 to 2.57).
Presence of CKD (versus no CKD) was also associated with
poorer outcomes with regard to the endpoints of in-hospital
case fatality or discharged to hospice (adjusted OR 1.31, 95%
CI: 1.28 to 1.33) and discharge destination other than directly
home (adjusted OR 1.06, 95% CI: 1.04 to 1.07). However,
analyses by stage of renal dysfunction showed that patients
with earlier stages of dysfunction had better outcomes than
those with normal function: patients with mild dysfunction
had lower odds of experiencing in-hospital case fatality or
being discharged to hospice (adjusted OR 0.88, 95% CI: 0.85
to 0.91), and those with mild dysfunction (adjusted OR 0.81,
95% CI: 0.80 to 0.83) or moderate dysfunction (adjusted OR
0.88, 95% CI: 0.86 to 0.90) had lower odds of discharge
destination other than home. The more advanced stages of
renal dysfunction (severe and failure) were both associated
with higher odds of experiencing in-hospital case fatality/
Table 5. Continued
Process Measures Category of CKD Unadjusted OR (95% CI)* P Value Adjusted OR (95% CI)* P Value
Anticoagulation prescribed at discharge
for AF patients
Mild kidney dysfunction
(GFR ≥60 to <90)
1.07 (1.01 to 1.14) 0.0222 1.18 (1.09 to 1.27) <0.0001
Anticoagulation prescribed at discharge
for AF patients
Moderate kidney dysfunction
(GFR ≥30 to <60)
0.95 (0.89 to 1.01) 0.0908 1.08 (0.99 to 1.18) 0.0737
Anticoagulation prescribed at discharge
for AF patients
Severe kidney dysfunction
(GFR ≥15 to <30)
0.68 (0.61 to 0.76) <0.0001 0.76 (0.67 to 0.87) 0.0001
Anticoagulation prescribed at discharge
for AF patients
Renal Failure (GFR<15) 0.64 (0.55 to 0.75) <0.0001 0.64 (0.53 to 0.77) <0.0001
Lipid-lowering agent prescribed at
discharge
CKD (GFR<60) 0.93 (0.91 to 0.95) <0.0001 0.96 (0.93 to 0.99) 0.0071
Lipid-lowering agent prescribed at
discharge
Mild kidney dysfunction
(GFR ≥60 to <90)
0.99 (0.96 to 1.02) 0.4052 1.03 (0.99 to 1.07) 0.1256
Lipid-lowering agent prescribed at
discharge
Moderate kidney dysfunction
(GFR ≥30 to <60)
0.94 (0.90 to 0.97) 0.0002 1.00 (0.96 to 1.05) 0.9794
Lipid to lowering agent prescribed at
discharge
Severe kidney dysfunction
(GFR ≥15 to <30)
0.87 (0.81 to 0.93) <0.0001 0.90 (0.83 to 0.97) 0.0068
Lipid-lowering agent prescribed at
discharge
Renal Failure (GFR<15) 0.84 (0.77 to 0.92) 0.0001 0.83 (0.74 to 0.92) 0.0003
Defect-free: compliance 100%
† CKD (GFR<60) 0.89 (0.87 to 0.90) <0.0001 0.91 (0.89 to 0.92) <0.0001
Defect-free: compliance 100% Mild kidney dysfunction
(GFR ≥60 to <90)
0.99 (0.97 to 1.01) 0.1954 1.00 (0.98 to 1.02) 0.8929
Defect-free: compliance 100% Moderate kidney dysfunction
(GFR ≥30 to <60)
0.91 (0.89 to 0.93) <0.0001 0.94 (0.92 to 0.97) <0.0001
Defect-free: compliance 100% Severe kidney dysfunction
(GFR ≥15 to <30)
0.78 (0.75 to 0.81) <0.0001 0.80 (0.77 to 0.84) <0.0001
Defect-free: compliance 100% Renal Failure (GFR<15) 0.73 (0.70 to 0.76) <0.0001 0.72 (0.68 to 0.76) <0.0001
CAD indicates coronary artery disease; CKD, Chronic Kidney Disease; GFR, glomerular ﬁltration rate; LDL, low-density lipoprotein; MI, myocardial infarction.
*Compared to normal deﬁned as a glomerular ﬁltration rate≥90. All models are adjusted for age, race, gender, medical history (atrial ﬁbrillation, prosthetic heart valve, previous stroke/TIA,
CAD/previous MI, carotid stenosis, peripheral vascular disease, hypertension, dyslipidemia, heart failure, and current smoking), systolic blood pressure (SBP) at admission, hospital size,
region, teaching status, and the number of annual stroke discharges from each hospital. Eligible patients were deﬁned as: (1) if LDL >100 mg/dL; (2) if patient was using lipid-lowering
agent at admission; or (3) if LDL was not measured and there were no contraindications to lipid-lowering medications.
†Defect-free care represents the proportion of subjects who received all of the measures that they were eligible for.
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than home (Table 6). Regression models that included the
measure of stroke severity (NIH Stroke Scale Score) showed a
similar pattern of results (not shown).
Discussion
In this large, contemporary nationwide study, we observed
that 1 of every 3 hospitalized ischemic stroke patients had
CKD, that the odds of dying in the hospital after adjusting for
major confounders was 44% higher for those patients with
CKD compared with those without CKD, and the independent
relation of kidney dysfunction with in-hospital mortality rose
progressively with worsening renal dysfunction. These results,
based on >600 000 ischemic stroke admissions at >1500
hospitals, deﬁnitively conﬁrm data from previously published
analyses of small single-center studies that showed a high
prevalence of CKD linked to poorer outcomes among
hospitalized ischemic stroke patients. In addition, our study
is the ﬁrst as far as we are aware to evaluate the quality of
stroke-related care among hospitalized ischemic stroke
patients by CKD presence and stage of kidney dysfunction,
ﬁnding that patients with evidence of renal dysfunction are
signiﬁcantly less likely to receive several effective therapies,
which are currently included in ischemic stroke hospitalization
performance and quality measures. This latter ﬁnding is in
accord with studies among patients hospitalized with acute
cardiovascular conditions that revealed greater underuse of
medications for vascular risk reduction as kidney function
declines.
13–15
Table 6. Unadjusted and Adjusted Odds Ratios Comparing Ischemic Stroke Patients With Various Stages of Kidney Dysfunction to
Those With Normal Kidney Function for 3 Outcome Measures
Outcome Measures Category of CKD Unadjusted OR (95% CI)* P Value Adjusted OR (95% CI)* P Value
In-hospital case fatality CKD (GFR<60) 1.90 (1.85 to 1.95) <0.0001 1.44 (1.40 to 1.47) <0.0001
In-hospital case fatality Mild kidney dysfunction (GFR
≥60 to <90)
1.28 (1.23 to 1.33) <0.0001 0.99 (0.95 to 1.03) 0.5626
In-hospital case fatality Moderate kidney dysfunction
(GFR ≥30 to <60)
1.99 (1.91 to 2.08) <0.0001 1.27 (1.22 to 1.32) <0.0001
In-hospital case fatality Severe kidney dysfunction
(GFR ≥15 to <30)
3.45 (3.27 to 3.65) <0.0001 2.14 (2.03 to 2.26) <0.0001
In-hospital case fatality Renal failure (GFR<15) 3.16 (2.94 to 3.41) <0.0001 2.39 (2.22 to 2.57) <0.0001
In-hospital case fatality or
discharged to hospice
CKD (GFR<60) 1.94 (1.91 to 1.98) <0.0001 1.31 (1.28 to 1.33) <0.0001
In-hospital case fatality or
discharged to hospice
Mild kidney dysfunction (GFR
≥60 to <90)
1.35 (1.31 to 1.38) <0.0001 0.88 (0.85 to 0.91) <0.0001
In-hospital case fatality or
discharged to hospice
Moderate kidney dysfunction
(GFR ≥30 to <60)
2.19 (2.12 to 2.25) <0.0001 1.07 (1.04 to 1.11) <0.0001
In-hospital case fatality or
discharged to hospice
Severe kidney dysfunction
(GFR ≥15 to <30)
3.43 (3.30 to 3.56) <0.0001 1.70 (1.63 to 1.78) <0.0001
In-hospital case fatality or
discharged to hospice
Renal failure (GFR<15) 2.91 (2.75 to 3.09) <0.0001 2.09 (1.96 to 2.23) <0.0001
Discharge destination other than
directly home
CKD (GFR<60) 1.60 (1.58 to 1.62) <0.0001 1.06 (1.04 to 1.07) <0.0001
Discharge destination other than
directly home
Mild kidney dysfunction (GFR
≥60 to <90)
1.23 (1.21 to 1.25) <0.0001 0.81 (0.80 to 0.83) <0.0001
Discharge destination other than
directly home
Moderate kidney dysfunction
(GFR ≥30 to <60)
1.78 (1.74 to 1.82) <0.0001 0.88 (0.86 to 0.90) <0.0001
Discharge destination other than
directly home
Severe kidney dysfunction
(GFR ≥15 to <30)
2.24 (2.17 to 2.31) <0.0001 1.10 (1.07 to 1.14) <0.0001
Discharge destination other than
directly home
Renal failure (GFR<15) 1.68 (1.61 to 1.75) <0.0001 1.11 (1.06 to 1.16) <0.0001
CAD indicates coronary artery disease; CKD, chronic kidney disease; GFR, glomerular ﬁltration rate; LDL, low-density lipoprotein; MI, myocardial infarction.
*Compared to normal deﬁned as a glomerular ﬁltration rate≥90. All models are adjusted for age, race, gender, medical history (atrial ﬁbrillation, prosthetic heart valve, previous stroke/TIA,
CAD/previous MI, carotid stenosis, peripheral vascular disease, hypertension, dyslipidemia, heart failure, and current smoking), systolic blood pressure (SBP) at admission, hospital size,
region, teaching status, and the number of annual stroke discharges from each hospital.
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examine the relationships of speciﬁc stages of kidney
dysfunction to various stroke hospitalization performance
measures and in-hospital outcome types. For instance, while
the overriding message from our results is that presence of
CKD is associated with lesser compliance with benchmarks of
stroke care and poorer outcomes, these results were primarily
driven by the more advanced stages of dysfunction, ie, severe
and failure. Indeed, hospitalized ischemic stroke patients with
mild dysfunction actually had similar or better in-hospital
outcomes when compared with those patients with normal
function. On the surface, this may seem counterintuitive since
proposed explanations for why vascular disease patients with
CKD may have poorer clinical outcomes than those without
CKD, is the frequent co-presence in the former patient group
of deleterious conditions like anemia, oxidative stress,
electrolyte imbalances, hyperhomocysteinemia, and chronic
inﬂammation.
16 However, in our study we observed that
patients with mild dysfunction versus normal function were
signiﬁcantly more likely to receive an antithrombotic pre-
scription within 48 hours of admission, be discharged on an
antithrombotic, receive anticoagulation at discharge if they
had a diagnosis of atrial ﬁbrillation or ﬂutter; showed a strong
trend towards being more likely to receive intravenous
thrombolysis; showed a non-signiﬁcant pattern of being more
likely to receive a lipid-lowering agent at discharge; and were
no less likely to receive smoking cessation counseling at
discharge, deep venous thrombosis prophylaxis, or overall
stroke hospitalization defect-free care. Although given the
nature of our study, we could not establish causality, it is not
inconceivable that better in-hospital care and perhaps signif-
icantly higher frequency of pre-morbid cardiovascular medi-
cations in patients with mild CKD versus normal function may
have led to similar or better outcomes among the former
patient group.
Underutilization of evidence-based treatments has similarly
been seen in other patient subgroups with chronic conditions
that place them at high vascular risk such as diabetes mellitus
and peripheral artery disease.
17,18 While the speciﬁc reasons
for why there is an underuse of evidence-based therapies
among hospitalized ischemic patients with CKD are not
exactly known, it stands to reason that potential contributors
to this evidence-practice treatment gap may include the facts
that the randomized trial evidence upon which several expert-
consensus recommendations for stroke treatment are based
typically excluded patients with major renal dysfunction,
9,10
patients with CKD are generally more likely to experience
adverse effects of many medications,
19 given the effect of
renal azotemia on platelet function patients with kidney
disease are at an increased risk for bleeding,
20 and
questionable therapeutic efﬁcacy.
21,22 All of the aforemen-
tioned factors may be leading clinicians caring for hospitalized
ischemic stroke patients to be more cautious about prescrib-
ing these therapies, despite the greater risk for cardiovascular
events and poor clinical outcomes in these patients.
2–6
However, emerging evidence suggests that the beneﬁts of
many secondary prevention drugs used in the treatment of
known vascular disease may be of equal or greater beneﬁtt o
those with renal dysfunction when compared with those
without,
19 and a published analysis of the GWTG-Stroke
dataset that looked at predictors of tPA-related sICH did not
ﬁnd any association between serum creatinine levels and risk
for tPA-related sICH.
23
This study has limitations. First, data were derived from
the medical record and depended on the accuracy and
completeness of clinical documentation (eg, it is conceivable
that some patients reported to be eligible for treatment were
not treated due to contraindications or intolerance that was
not documented; or very ill patients with advanced CKD in the
process of being discharged to hospice for terminal care were
not candidates for certain treatments). Second, although
hospitals are instructed to include all consecutive admissions
or to take a random sample, these processes are not audited
so the potential for selection bias exists. Third, while we
controlled for known confounders, unmeasured confounding
could have affected our results. Fourth, our ﬁndings may not
necessarily apply to hospitals that differ in patient charac-
teristics or care patterns from GWTG-Stroke hospitals. Fifth,
we only examined in-hospital outcomes, therefore, the longer-
term impact of CKD or of the differences in quality of care
identiﬁed in this study on stroke-related outcomes were not
determined. Next, although the MDRD formula is the
preferred method for estimating renal function, it generally
should be applied when renal function is stable, and this may
not be the case for many patients admitted with acute
ischemic stroke, potentially limiting its usefulness in this
population. However, our intent was not to determine precise
renal function but to estimate the degree of renal impairment
in a large cohort of patients hospitalized with acute ischemic
stroke. In addition, admission creatinine was not available in
all patients, which may have introduced bias into the ﬁndings.
Finally, we were unable to deﬁnitively establish an association
between hospital care performance measures and outcomes
or pinpoint the mechanisms by which renal dysfunction may
affect mortality.
In conclusion, in this sizeable multi-site study we conﬁrmed
that renal dysfunction prevalence is high and associated with
poor clinical outcomes among patients hospitalized with an
ischemic stroke. Furthermore, we found that despite higher
rates of in-hospital mortality linked to worsening renal
dysfunction, ischemic stroke patients with advanced stages
of dysfunction were signiﬁcantly less likely to receive
evidence-based pharmacologic and non-pharmacologic
management strategies during their index hospitalization.
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enhance the care of hospitalized patients with ischemic
stroke and kidney dysfunction.
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